PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.

Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they care. By providing practical guidance on how to effectively integrate the latest evidence and expert recommendations into real-world clinical scenarios, this activity provides participating clinicians with the necessary tools to effectively navigate the rapidly changing landscape for PN. Additionally, patient videos are utilized throughout to convey key information regarding the burden of PN and optimal management strategies. Upon completion of this activity, participants should be better able to: Discuss the impact on quality of life and economic implications of prurigo nodularis (PN), Describe the pathophysiology of PN as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Evaluate emerging treatment options for PN in the context of mechanism of action, efficacy, and safety, Treat PN in accordance with current evidence and expert recommendations, recognizing that an effective treatment approach should be based on clinical judgment and tailored to the individual needs of the patient.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it’s on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what’s to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/MRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of the airway epithelium in severe asthma treatment. Upon completion of this activity, participants should be better able to: Apply the latest pathophysiologic insights into the role of epithelial alarmins in the development of inflammation and structural changes in the airways to the treatment of patients with severe asthma, Discuss the clinical implications of biologic treatment that is not limited by phenotype or biomarker for patients with severe asthma whose disease remains uncontrolled despite standard treatment, Identify patients with severe asthma who may be eligible for treatment with novel biologic therapies that target epithelial alarmins.

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient’s clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

Go online to PeerView.com/WFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the last two decades, there have been very limited advancements in the treatment of HR+, HER2- early breast cancer, and a particularly marked unmet need has existed for patients at the highest risk of recurrence. Fortunately, there is new hope of improved outcomes for these patients following the recent FDA approval of the first CDK4 and 6 inhibitor for the adjuvant treatment of patients with HR+, HER2-, node+ early breast cancer at high risk of recurrence and a Ki-67 score ≥20%. Shortly thereafter, guideline updates were released that recommended adjuvant CDK4 and 6 inhibitor therapy combined with endocrine therapy to a broader population of patients at high risk of recurrence. The emergence of this new therapeutic option along with varied indications and recommendations has resulted in much uncertainty about which patients should and should not receive adjuvant CDK4 and 6 inhibitor therapy, and how to best integrate it into clinical practice to meaningfully impact outcomes in this challenging patient population. In this educational activity, two leading experts deliver pertinent updates and use patient cases to provide practical guidance for the multidisciplinary team on how to navigate the changing standards of care in HR+, HER2- early breast cancer. Learn how to identify the most appropriate patients who can achieve the highest absolute benefit from adjuvant CDK4 and 6 inhibition, and ensure that those with a particularly poor prognosis are not excluded from this therapy. Additionally, receive guidance on how to recognize and manage treatment-related adverse events so that patients continue to adhere to CDK4 and 6 inhibitor therapy and derive maximum benefit from it in the adjuvant setting. Upon completion of this activity, participants should be better able to: Discuss the evidence, tools, and strategies for risk assessment and stratification in HR+, HER2- early breast cancer to guide treatment selection, including identification of candidates for adjuvant CDK4 and 6 inhibitor therapy, Integrate the latest safety and efficacy data on adjuvant CDK4 and 6 inhibitor therapy into clinical decisions for patients with high-risk, HR+, HER2- early breast cancer, Incorporate modern risk assessment approaches, supporting evidence, regulatory and guideline recommendations, adverse event prevention/management strategies, and shared decision-making into the establishment of individualized treatment plans for patients with HR+, HER2- early breast cancer to improve outcomes in this patient population, including reducing the risk of recurrence in patients with poor prognosis.

Go online to PeerView.com/KMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes. Upon completion of this activity, participants should be better able to: Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment, Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate, Collaborate with clinical colleagues to ensure that evidence-based, guideline-recommended treatment is discussed and offered to patients with AF to reduce the risk of stroke, Educate patients with AF about the heightened risk of stroke and the importance of anticoagulation therapy.